Kassi Filkins

This new technology, the MacuMira system, is a non-invasive treatment now available in more than 150 clinics across Canada.

Kalaris Therapeutics initiates a phase 1b/2 study for TH103, targeting neovascular age-related macular degeneration and advancing retinal disease treatment.

Belite Bio completes its phase 3 trial for tinlarebant, a potential first treatment for Stargardt disease, with results expected in late 2025.

Optain Health secures $26 million in Series A funding to enhance AI-driven retinal disease detection and expand its technology.

Bausch + Lomb reveals promising results for the enVista Envy IOL, showcasing superior vision outcomes in cataract surgery patients.

In both trials, Beacon’s lead program, laru-zova, was found to be well-tolerated by SKYLINE participants through month 36 and DAWN patients at month 9 or longer.

Roche reveals promising results for Vabysmo in treating eye diseases, showcasing significant vision improvements and safety in recent clinical trials.

Ashvattha Therapeutics reveals phase 2 results for migaldendranib, showing significant vision improvements and reduced injection needs in retinal disease patients.

Roche's Contivue platform gains EU CE mark, offering innovative treatment for neovascular AMD with fewer injections and promising long-term vision outcomes.

A study reveals similar risks of sight-threatening diabetic retinopathy in pregnant women with type 1 diabetes compared to nonpregnant controls.

Kriya is developing gene therapies targeting chronic diseases such as geographic atrophy, trigeminal neuralgia, and type 1 diabetes.

Alcon showcases new data at APACRS 2025, emphasizing advancements in IOL technology and surgical precision for improved patient outcomes.

jCyte initiates patient dosing in a new trial for famzeretcel, aiming to transform treatment options for retinitis pigmentosa.

This phase 2b/3 trial follows new, positive 2-year data from the phase 2 ALTITUDE trial, in which sura-vec was well-tolerated in subjects with non-proliferative diabetic retinopathy

Neurotech Pharmaceuticals announced the first commercial manufacturing, shipment, and surgical procedure of ENCELTO, the first and only FDA-approved treatment for adults with idiopathic Macular Telangiectasia Type 2.

The Portal study is a long-term extension of the phase 3 Archway study

EyePoint Pharmaceuticals completes enrollment for the LUCIA trial, advancing DURAVYU's potential as a new treatment for wet AMD.

Opus Genetics partners with the Global RDH12 Alliance to advance gene therapy for inherited retinal disease, aiming for FDA application by late 2025.

KIO-104 is for the treatment of a wide range of ocular diseases, including ocular inflammation, uveitis, age-related macular degeneration (AMD), and complications as a result of refractive surgery.

These updates support Ocugen in its efforts to pursue its goal of 3 biologics license applications (BLA) in the next 3 years.

AAVB-039 advances gene therapy for Stargardt disease, aiming for innovative treatments for inherited retinal disorders.

SAR446597 is a one-time intravitreal gene therapy treatment for the treatment of geographic atrophy

KAIST researchers unveil a new microbial strain for efficient, eco-friendly lutein production.

MCO-010 is a gene-agnostic therapy for retinitis pigmentosa.

KALA Bio completes enrollment in CHASE trial, advancing KPI-012 for treating persistent corneal epithelial defects. Topline results are expected by the end of Q3 2025.